AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have been outstanding dividend and growth stocks for the better part of the last decade. These two pharma giants have generated total returns on capital (including dividends) of 52% and 97%, respectively, over the last five years.
Nonetheless, AbbVie and Lilly have both run into trouble in 2019 due to a mix of company-specific issues and industrywide headwinds. Which of these top pharma stocks has the best chance of breaking out of this recent funk? Let's take a look at the bull and bear case for each stock to find out.
Image source: Getty Images.